At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 67 enrolled
Drug / intervention
perioperative treatmentdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT): A Phase II Study (GASPAR)
In Brief
A Phase 2 clinical trial evaluating perioperative treatment for Gastric Cancer by AJCC V8 Stage and Resectable Carcinoma. Completed, enrolled 67 participants across 13 sites.
Detailed Summary
Multicenter, open-label, non randomized, phase 2 trial in resectable gastric or gastroesophageal junction adenocarcinoma: Perioperative Treatment by Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance
CollaboratorsNational Cancer Institute, France
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedFeb 2021
Enrollment StartJun 2021
Primary CompletionMar 2024
Study CompletionNov 2025
TodayJul 2026
First PostedFeb 3, 2021
Enrollment StartJun 28, 2021
Primary CompletionMar 1, 2024
Study CompletionNov 27, 2025
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 5.4 years ago
Interventions
perioperative treatmentdrug
FLOT + Spartalizumab